In a phase I/II study on the efficacy of the MSLN-targeting recombinant immunotoxin, LMB-100, in combination with nab-paclitaxel for the treatment of advanced pancreatic cancer, a correlation between CA19-9 response to investigational treatment and MSLN expression was suggested [35, 36]. This evidence concerns the gene MSLN and familial pancreatic carcinoma.